ColemanR.E.: Metastatic bone disease: clinical features, pathophysiology and treatment strategies.Cancer Treat Rev,27: 165–176, 2001.
2.
Van PoznakC.H.: The use of biphosphonates in patients with breast cancer.Cancer Control,9: 480–489, 2002.
3.
CentenoC., SanzA., VaraF.: Bone metastasis: clinical manifestations and complications. A cross-disciplinary treatment.Med Pal,8: 100–108, 2001.
4.
BrownH.K., HealeyJ.H.: Metastatic cancer to the bone. In: DeVitaV.T., HellmannS.Jr., RosembergS.A.: Cancer, principles and practice of oncology.Philadelphia, ed Lippincott, pp 2713–2717, 2001.
5.
MirelsH.: Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathological fractures.Clin Orthop Rel Res,249: 256–264, 1989.
6.
RosenL.S., GordonD., KaminskiM.: Zoledronic acid vs pamidronate in the treatment of skeletal metastasis in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.Cancer J,7: 377–387, 2001.
7.
SteinS.H., DavidsonR., TweedA.: Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer.Proc ASCO,22: 46 (A 2997), 2003.
8.
HillnerB.E., IngleJ.N., ChlebowskiR.T.: ASCO 2003 update on the role of bisphosphonates and bone health issue in women with breast cancer.J Clin Oncol,21: 4042–4057, 2003.
9.
MuhlbauerR.C., BaussF., SchenkR.: BM 210955: a potent new bisphosphonate to inhibit bone resorption.J Bone Miner Res,6: 1003–1011, 1991.
10.
BaussF., MuhlbauerR.C.: Ibandronate monosodium salt monohydrate.Drugs Fut,19: 13–16, 1994.
11.
FromigueO., LagneauxL., BodyJ.J.: Bisphosphonates induce breast cancer cell death in vitro.J Bone Miner Res,15: 2211–2221, 2000.
12.
NeugebauerG., KohlerW., AkinkunmiL.: Influence of peak ibandronic acid concentrations after 6 mg iv administration with shortened infusion time (15 and 30 minutes) on renal safety in man.Proc ASCO,20(486 A), 2001.
13.
RalstonS.H., ThiebaudD., HermannZ.: Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.Br J Cancer,75: 295–300, 1997.
14.
PecherstorferM., SteinhauerE.U., RizzoliR.: Efficacy and safety of ibandronate in the treatment of hypercalcaemia of malignancy: a randomised multicentric comparison to pamidronate.Support Care Cancer,11: 539–547, 2003.
15.
BodyJ.J., DielI.J., LichinitserM.R.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.Ann Oncol,14: 1399–1405, 2003.
16.
ScottM., MocksJ., GivensS.: Morbidity measures in presence of recurrent composite endpoints.Pharmaceut Statist,2: 39–49, 2003.
17.
TripathyD., BodyJ.J., DielI.: Oral daily ibandronate: efficacy in reducing skeletal complications in patients with metastatic bone disease from breast cancer.Proc ASCO,22: 46 (185 A), 2003.
18.
BodyJ.J., KanisJ., DielI.: Risk reductions in metastatic breast cancer: multivariate Poisson regression analysis of oral and iv ibandronate.Proc ASCO,22: 46 (184 A), 2003.
19.
ManciniI., DumanJ.C., TothC.: Short-term treatment with the bisphosphonate ibandronate for opioid-resistant metastatic bone pain.Bone, 30 (Suppl 3):51(56 A), 2002.
20.
HeidenreichA., OhlmannC., OlbertP.: High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Presented at ECCO 12, Copenhagen (Denmark), 21-25 September 2003.
